Cargando…
From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress
Glioblastoma, a rare, and highly lethal form of brain cancer, poses significant challenges in terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients alike. Despite advancements in brain cancer research driven by a technological revolution, translating our und...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587102/ https://www.ncbi.nlm.nih.gov/pubmed/37857607 http://dx.doi.org/10.1038/s41392-023-01637-8 |
_version_ | 1785123285741076480 |
---|---|
author | Dewdney, Brittany Jenkins, Misty R. Best, Sarah A. Freytag, Saskia Prasad, Krishneel Holst, Jeff Endersby, Raelene Johns, Terrance G. |
author_facet | Dewdney, Brittany Jenkins, Misty R. Best, Sarah A. Freytag, Saskia Prasad, Krishneel Holst, Jeff Endersby, Raelene Johns, Terrance G. |
author_sort | Dewdney, Brittany |
collection | PubMed |
description | Glioblastoma, a rare, and highly lethal form of brain cancer, poses significant challenges in terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients alike. Despite advancements in brain cancer research driven by a technological revolution, translating our understanding of glioblastoma pathogenesis into improved clinical outcomes remains a critical unmet need. This review emphasises the intricate role of receptor tyrosine kinase signalling pathways, epigenetic mechanisms, and metabolic functions in glioblastoma tumourigenesis and therapeutic resistance. We also discuss the extensive efforts over the past two decades that have explored targeted therapies against these pathways. Emerging therapeutic approaches, such as antibody-toxin conjugates or CAR T cell therapies, offer potential by specifically targeting proteins on the glioblastoma cell surface. Combination strategies incorporating protein-targeted therapy and immune-based therapies demonstrate great promise for future clinical research. Moreover, gaining insights into the role of cell-of-origin in glioblastoma treatment response holds the potential to advance precision medicine approaches. Addressing these challenges is crucial to improving outcomes for glioblastoma patients and moving towards more effective precision therapies. |
format | Online Article Text |
id | pubmed-10587102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-105871022023-10-21 From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress Dewdney, Brittany Jenkins, Misty R. Best, Sarah A. Freytag, Saskia Prasad, Krishneel Holst, Jeff Endersby, Raelene Johns, Terrance G. Signal Transduct Target Ther Review Article Glioblastoma, a rare, and highly lethal form of brain cancer, poses significant challenges in terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients alike. Despite advancements in brain cancer research driven by a technological revolution, translating our understanding of glioblastoma pathogenesis into improved clinical outcomes remains a critical unmet need. This review emphasises the intricate role of receptor tyrosine kinase signalling pathways, epigenetic mechanisms, and metabolic functions in glioblastoma tumourigenesis and therapeutic resistance. We also discuss the extensive efforts over the past two decades that have explored targeted therapies against these pathways. Emerging therapeutic approaches, such as antibody-toxin conjugates or CAR T cell therapies, offer potential by specifically targeting proteins on the glioblastoma cell surface. Combination strategies incorporating protein-targeted therapy and immune-based therapies demonstrate great promise for future clinical research. Moreover, gaining insights into the role of cell-of-origin in glioblastoma treatment response holds the potential to advance precision medicine approaches. Addressing these challenges is crucial to improving outcomes for glioblastoma patients and moving towards more effective precision therapies. Nature Publishing Group UK 2023-10-20 /pmc/articles/PMC10587102/ /pubmed/37857607 http://dx.doi.org/10.1038/s41392-023-01637-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Dewdney, Brittany Jenkins, Misty R. Best, Sarah A. Freytag, Saskia Prasad, Krishneel Holst, Jeff Endersby, Raelene Johns, Terrance G. From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress |
title | From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress |
title_full | From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress |
title_fullStr | From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress |
title_full_unstemmed | From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress |
title_short | From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress |
title_sort | from signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587102/ https://www.ncbi.nlm.nih.gov/pubmed/37857607 http://dx.doi.org/10.1038/s41392-023-01637-8 |
work_keys_str_mv | AT dewdneybrittany fromsignallingpathwaystotargetedtherapiesunravellingglioblastomassecretsandharnessingtwodecadesofprogress AT jenkinsmistyr fromsignallingpathwaystotargetedtherapiesunravellingglioblastomassecretsandharnessingtwodecadesofprogress AT bestsaraha fromsignallingpathwaystotargetedtherapiesunravellingglioblastomassecretsandharnessingtwodecadesofprogress AT freytagsaskia fromsignallingpathwaystotargetedtherapiesunravellingglioblastomassecretsandharnessingtwodecadesofprogress AT prasadkrishneel fromsignallingpathwaystotargetedtherapiesunravellingglioblastomassecretsandharnessingtwodecadesofprogress AT holstjeff fromsignallingpathwaystotargetedtherapiesunravellingglioblastomassecretsandharnessingtwodecadesofprogress AT endersbyraelene fromsignallingpathwaystotargetedtherapiesunravellingglioblastomassecretsandharnessingtwodecadesofprogress AT johnsterranceg fromsignallingpathwaystotargetedtherapiesunravellingglioblastomassecretsandharnessingtwodecadesofprogress |